Patients with type 1 diabetes who used Insulet's Omnipod 5 Automated Insulin Delivery System, the first-ever tubeless and wearable insulin pump, achieved considerable average improvements in A1C and the duration in which they stayed within the target glucose range as recommended by the American Diabetes Association, according to findings to be presented at the Endocrine Society's annual virtual meeting. Omnipod 5, which is currently under review by the FDA, especially helped adults and adolescents with type 1 diabetes spend less time in hypoglycemia, said lead researcher Trang Ly.

The FDA has cleared Insulet's Omnipod Dash alternate controller-enabled infusion pump as an integrated insulin pump. The system can hold up to 200 units of U-100 insulin and features a touch-screen personal diabetes manager for control of the pod.

Insulet has secured 510(k) clearance from the FDA for its Omnipod Dash insulin-management system, which allows the company's Personal Diabetes Manager to be wirelessly connected to its tubeless, waterproof insulin pump. The system, which will be released early next year in the US, also connects to the Omnipod View and Omnipod Display apps, allowing insulin therapy data to be accessed by caregivers and users.

Ascensia Diabetes Care reached a global commercial agreement with Insulet, expanding their worldwide development partnership aimed at integrating Insulet's next-gen Omnipod system, Omnipod Dash, and Ascensia's Contour Next One blood glucose monitor. Under the nonexclusive commercial deal, the Contour Next One meter will be distributed by Insulet with its Omnipod Dash insulin delivery system.

Insulet will integrate its next-generation OmniPod insulin pump with LifeScan's OneTouch blood glucose monitor, under a deal struck with the Johnson & Johnson subsidiary. The resulting technology is targeted for commercial release in the middle of next year, said Peter Devlin, Insulet's chief commercial officer.